Identification of Novel Immunogenic Proteins from *Mycoplasma bovis* and Establishment of an Indirect ELISA Based on Recombinant E1 Beta Subunit of the Pyruvate Dehydrogenase Complex

Zhenhong Sun¹, Ping Fu¹, Kai Wei, Haiyan Zhang, Yuewei Zhang, Jian Xu, Fei Jiang, Xu Liu, Wei Xu, Wenxue Wu*

Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing, P. R. China

**Abstract**

The pathogen *Mycoplasma bovis* (*M. bovis*) is a major cause of respiratory disease, mastitis, and arthritis in cattle. Screening the key immunogenic proteins and updating rapid diagnostic techniques are necessary to the prevention and control of *M. bovis* infection. In this study, 19 highly immunogenic proteins from *M. bovis* strain PD were identified using 2-dimensional gel electrophoresis, immunoblotting and MALDI-TOF/TOF MS. Of these 19 proteins, pyruvate dehydrogenase E1 component beta subunit (PDHB) showed excellent immune reactivity and repeatability. PDHB was found to be conserved in different *M. bovis* isolates, as indicated by Western blot analysis. On the basis of these results, a rPDHB-based indirect ELISA (iELISA) was established for the detection of serum antibodies using prokaryotically expressed recombinant PDHB protein as the coating antigen. The specificity analysis result showed that rPDHB-based iELISA did not react with other pathogens assessed in our study except *M. agalactiae* (which infects sheep and goats). Moreover, 358 serum samples from several disease-affected cattle feedlots were tested using this iELISA system and a commercial kit, which gave positive rates of 50.8% and 39.9%, respectively. The estimated Kappa agreement coefficient between the two methods was 0.783. Notably, 39 positive serum samples that had been missed by the commercial kit were all found to be positive by Western blot analysis. The detection rate of rPDHB-based iELISA was significantly higher than that of the commercial kit at a serum dilution ratio of 1:5120 to 1:10,240 (P<0.05). Taken together, these results provide important information regarding the novel immunogenic proteins of *M. bovis*. The established rPDHB-based iELISA may be suitable for use as a new method of antibody detection in *M. bovis*.

**Introduction**

*Mycoplasma bovis* (*M. bovis*) is a major but often overlooked pathogen. It mainly causes respiratory disease, mastitis, arthritis, keratoconjunctivitis, and otitis. *M. bovis* was first isolated from a case of severe mastitis in cattle in 1961 [1]. It has since been reported to be connected with bovine respiratory disease [2]. In China, it was first isolated in 2008, from the lungs of calves infected with pneumonia [3]. This disease exists worldwide today. In Europe, about 25–33% of cases of calf pneumonia are caused by or associated with *M. bovis*. In the U.S., *M. bovis* is responsible for annual losses of USD 140 million resulting from bovine respiratory disease and breast disease, with a maximum infection rate of up to 70% per cattle feedlot [4–6].

Under natural conditions, *M. bovis* infection is difficult to identify and easy to confuse with contagious pleuropneumonia because their clinical symptoms and pathologic changes are very similar. This leaves laboratory differential diagnosis as the best available way to identify *M. bovis* infection. Generally, serological diagnosis is more sensitive than *M. bovis* isolation, especially for the chronic cases or animals treated with antibiotics [5]. Currently, a few commercial indirect ELISA kits have been used for this purpose. The commonly used are the *Mycoplasma bovis* Antibody Test Kit which is produced by Canada’s Biovet Company and Bio-X *Mycoplasma bovis* ELISA Kit produced by Belgium’s Bio-X Diagnostics Company. Most kits are based on whole-cell proteins, and the effects with respect to the detection of *M. bovis* infection in different geographic regions have yet to be verified. However, the use of specific, highly pure antigens with high affinity to antibodies as coating antigens may render the diagnosis more accurate.

Early reported *M. bovis* immunogenic proteins involved variable surface proteins (Vsps). These membrane-surface antigens can vary in phase and size. This involves high-frequency rearrangements of the DNA region encoding the Vsp genes. These rearrangements play a major role in evading the immune system of the host [7,8]. In recent years, several relatively conserved immunogenic proteins have been discovered. These include the conserved P26 [9] and P48 [10] lipoproteins, heat-shock proteins...
and prevention of development of more effective approaches to both the diagnosis and prevention of \textit{M. bovis}. More immunogenic proteins must be identified to facilitate development of more effective approaches to both the diagnosis and prevention of \textit{M. bovis}.

Proteome analysis is a useful complementary method of studying pathogens. It facilitates genome annotation and protein identification [13,14]. Immunoproteomics, which combines conventional proteomics with serology, is a powerful method of identifying immunodominant antigens that have diagnostic and protective value [15]. In this study, 19 immunogenic proteins were identified in a strain of \textit{M. bovis} that had been isolated in China. These proteins were identified using immunoproteomics with four positive sera (Table S1) collected from the disease-affected cattle feedlots in different provinces. An iELISA method of detecting serum antibodies was established based on prokaryotically expressed antigen protein E1 beta subunit of the pyruvate dehydrogenase complex (PDHB). It was found to be highly sensitive and specific.

Results

Two-dimensional gel electrophoresis (2-DE) and immunoblotting

To separate the whole-cell proteins of \textit{M. bovis}, IPG strips of different pH ranges (pH 3–10 and pH 4–7) were used for 2-DE (Fig. 1A). This 2-DE process was shown to be reproducible by running different batches of protein samples to each IPG strip three times (data not shown). About 570 prominent protein spots, with molecular weights ranging from 15 to 130 kDa, were detected in Coomassie brilliant blue R-350 stained 2-DE gels with pH 3–10 IPG strips (17 cm, NL) (Fig. 2A). The isoelectric points (pI) of most proteins were concentrated within the range of 4–7. Taking into account that there are 765 proteins encoded by the genome of \textit{M. bovis} reference strain PG45, the rate of coverage of proteins separated in the present study was found to be 74.5%.

According to the isoelectric points of most proteins, IPG strips of pH 4–7 were selected for use in the following tests to facilitate better separation of the proteins (Fig. 2C).

The proteins separated in 2-DE gels with pH 3–10 and pH 4–7 IPG strips were blotted onto PVDF membranes, respectively. Then, each immunoblot assay was performed using the strongly positive sera A, B, C, and D (Table S1), collected from naturally infected cattle. About 60 and 35 spots were found to be positive on the two PVDF membranes, as shown in Figs. 2B and 2D. These immunoreactive protein spots showing good reproducibility were identified using each strongly positive serum. No positive spot was detected in the test using the negative sera (data not shown).

Immunogenic proteins identified using MALDI-TOF/TOF MS and bioinformatics analysis

At first, 21 and 11 immunoreactive protein spots with good reproducibility were excised from 2-DE gels stained with Coomassie with pH 3–10 and 4–7 IPG strips, respectively. MALDI-TOF/TOF MS analysis indicated the presence of 31 protein spots, corresponding to a total of 19 different proteins. Of these, 12 proteins corresponded to single spots and 7 proteins were represented by multiple immunoreactive spots, indicating post-translational modifications such as chemical modification and proteolytic cleavage. The information regarding the identity, isoelectric point, molecular weight, identification score, and protein score of these immunogenic proteins are shown in Table 1.

![Figure 1. Extraction of the whole-cell proteins of \textit{M. bovis} strain PD and expression of rPDHB protein. (A1) The extracted whole-cell proteins were separated by SDS-PAGE. (A2) Purity analysis of the recombinant His-tagged PDHB protein by SDS-PAGE. (B) Purified rPDHB protein was subjected to Western blot analysis using an anti-His-tag antibody. doi:10.1371/journal.pone.0088328.g001](image-url)
mycoplasma species (isolated from cattle, sheep and goats) (Table 2). These data showed the protein PDHB to be structurally conserved within the *M. bovis* cluster.

**Expression of *M. bovis* PDHB**

The 987 bp gene encoding PDHB was amplified from the genome of *M. bovis* strain PD and cloned into a prokaryotic vector. Then recombinant PDHB (rPDHB) containing six histidine residues was expressed in *E. coli*, as illustrated in Fig. 1A. The Western blot analysis result indicated the presence of an immunoreactive band of about 37 kDa corresponding to the rPDHB (Fig. 1B), with a slightly higher molecular mass than the native protein of *M. bovis*.

**Antigenicity analysis of *M. bovis* PDHB**

In order to examine whether the antigenicity of *M. bovis* PDHB was species-specific, Western blot analysis was performed to assess the reactivity of the prepared rabbit anti-rPDHB polyclonal antibody and the whole-cell proteins of eight *M. bovis* isolates. As shown in Fig. 3, all eight *M. bovis* strains isolated from different regions reacted with the rabbit anti-rPDHB polyclonal antibody. For the reaction with *M. bovirhinis*, *M. ovipneumoniae*, *M. agalactiae*, bovine viral diarrhea virus (BVDV), bovine parainfluenza virus type 3 (BPIV3), and infectious bovine rhinotracheitis virus (IBRV), all these pathogens failed to be recognized by the anti-rPDHB polyclonal antibody except *M. agalactiae* (Fig. S1). All pathogens in the present study were identified using specific PCR, as shown in Fig. S2. The results indicated that the antigenicity of *M. bovis* PDHB was similar to that of *M. agalactiae* PDHB but markedly different from that of other pathogens.

**Establishment of rPDHB-based iELISA**

According to the immunogenicity and antigenicity of *M. bovis* PDHB, a rPDHB-based iELISA was established to confirm the

---

**Figure 2. Two-dimensional gel electrophoresis (2-DE) and immunoblotting of the whole-cell proteins of *M. bovis* strain PD.** First, 350 μg and 100 μg of protein were separated by IEF using (A) a pH 3–10 IPG strip and (C) a pH 4–7 IPG strip, respectively. This was followed by SDS-PAGE on 12% gels and staining with Coomassie brilliant blue R-350. Immunoblotting was performed using each of the four antisera (Table S1) from naturally infected cattle with three replicates. The immunoreactive protein spots on PVDF membranes B and D contained all spots with good reproducibility as identified by each of the four positive sera. These corresponded to the proteins separated by 2-D gels A and C, respectively. pI values are shown on top, and the standard molecular weights are shown to the left of the gels. The spot numbers correspond to those identified by MS and listed in Table 1.

doi:10.1371/journal.pone.0088328.g002
feasibility of rPDHB as a diagnostic antigen. Standard positive and negative sera were used to optimize the reaction conditions. Eventually, the best reaction conditions were selected as follows: the concentration of rPDHB used for coating was 100 ng/well, blocking buffer was 10% sheep serum, the best dilutions of serum sample and secondary antibody were 1:160 and 1:2000 (v/v), respectively, and the cutoff value was 0.316.

To examine the specificity of this iELISA, the prepared positive sera of other pathogens, including *Mycoplasma mycoides subsp. mycoides SC* (**Mmm** SC), *M. agalactiae*, *M. bovirhinis*, *M. ovipneumoniae*, BVDV, BPIV3, and IBRV, were tested. According to the Table 1. *M. bovis* proteins identified by mass spectrometry and reactions with sera from naturally infected cattle in immunoblotting experiments.

| Spot no. | Protein | NCBI ID | pl | MW (kDa) | Identification scores | Protein score | C.I. %a | COGb |
|----------|---------|---------|----|----------|---------------------|--------------|--------|------|
| 1        | Peptide chain release factor 1 | gi|313678884 | 5.30 | 40.43 | 842 | 100 | J |
| 2        | Pyrimidine-nucleoside phosphorylase | gi|313678400 | 8.09 | 47.26 | 1020 | 100 | F |
| 3        | Glyceraldehyde-3-phosphate dehydrogenase, type 1 | gi|313678191 | 7.70 | 36.85 | 814 | 100 | G |
| 4        | Pyruvate dehydrogenase E1 component subunit alpha | gi|313678230 | 6.13 | 41.33 | 435 | 100 | C |
| 5        | L-lactate dehydrogenase | gi|313678425 | 6.35 | 35.02 | 962 | 100 | C |
| 6        | Oxidoreductase, zinc-binding dehydrogenase family | gi|313678628 | 6.51 | 37.96 | 778 | 100 | E |
| 7        | Acetate kinase | gi|339320670 | 6.16 | 44.27 | 889 | 100 | C |
| 8        | D-xyloside 5-phosphate/D-fructose 6-phosphate phosphoketolase | gi|313678257 | 6.30 | 89.91 | 929 | 100 | G |
| 9        | Pyruvate dehydrogenase complex, E3 component, dihydrolipoamide dehydrogenase | gi|313678233 | 6.50 | 58.80 | 569 | 100 | C |
| 10       | Adenylate kinase | gi|344204920 | 8.53 | 24.33 | 76 | 99.91 | F |
| 11       | Thymidine phosphorylase(TDPASE) | gi|339321078 | 7.60 | 47.28 | 995 | 100 | F |
| 12       | Translation elongation factor P | gi|313678493 | 5.36 | 21.00 | 148 | 100 | J |
| 13       | Cell division protein ftsZ | gi|339320924 | 4.86 | 41.95 | 110 | 100 | D |
| 14       | Thioredoxin-disulflde reductase | gi|313678228 | 5.50 | 33.89 | 164 | 100 | O |
| 15       | Pyruvate dehydrogenase E1 component subunit beta | gi|313678231 | 5.44 | 36.18 | 1070 | 100 | C |
| 16       | Phosphopentomutase | gi|313678465 | 5.32 | 44.02 | 854 | 100 | G |
| 17       | Lipoyltransferase and lipoate-protein ligase | gi|313678142 | 5.43 | 39.78 | 693 | 100 | H |
| 18       | Translation elongation factor Ts | gi|313678643 | 5.23 | 32.67 | 438 | 100 | J |
| 19       | Purine nucleoside phosphorylase | gi|313678401 | 5.33 | 25.92 | 956 | 100 | C |

Protein spots from 2-DE were sequenced using MALDI-TOF/TOF MS and identified by searching mycoplasma databases using the MASCOT search engine 2.2. A GPS explorer protein confidence index $\geq95\%$ were used for further manual validation.

$^a$C.I. %: the confidence interval for the protein score.

$^b$COG database functional classes: (C) energy production and conversion, (D) cell cycle control, cell division, chromosome partitioning, (E) amino acid transport and metabolism, (F) nucleotide transport and metabolism, (G) carbohydrate transport and metabolism, (H) coenzyme transport and metabolism, (J) translation, ribosomal structure and biogenesis, (O) post-translational modification, protein turnover, chaperones.

doi:10.1371/journal.pone.0088328.t001

Table 2. Homology of PDHB from the *M. bovis* strain PD and other mycoplasmas.

| Mycoplasmas | NCBI Reference sequence | Homology |
|-------------|-------------------------|----------|
| *Mycoplasma bovis* PG45 | YP_004055971.1 | 100.0% |
| *Mycoplasma bovis* Hubel-1 | YP_004683146.1 | 99.7% |
| *Mycoplasma bovis* HB0801 | YP_006470739.1 | 99.7% |
| *Mycoplasma agalactiae* PG2 | YP_001256238.1 | 98.2% |
| *Mycoplasma bovigenitalium* | WP_004420033.1 | 66.2% |
| *Mycoplasma ovipneumoniae* | WP_010321080.1 | 58.5% |
| *Mycoplasma mycoides subsp. capri str. GM12* | ACU79371.1 | 47.9% |
| *Mycoplasma mycoides subsp. mycoides SC str. PG1* | NP_975265.1 | 47.9% |
| *Mycoplasma capricolum subsp. capricolum* ATCC 27343 | YP_424213.1 | 47.3% |

Mycoplasmas shown on the list were selected using the NCBI BLAST server, basing on the principle of recent homology. Then the amino acid sequences of these PDHBs were downloaded from NCBI, and DNAstar software (version 5.0) was used to analyze the homology.

doi:10.1371/journal.pone.0088328.t002
Performance of rPDHB-based iELISA and a commercial kit

Figure 3. Antigenicity of PDHBs from different M. bovis isolates.

The whole-cell proteins of eight M. bovis isolates were separated by SDS-PAGE, blotted onto a PVDF membrane, and subjected to Western blot analysis with a rabbit anti-rPDHB polyclonal antibody. The positions of molecular mass markers are indicated at the left in kDa. Lanes 1–8: M. bovis strain PD, PG45, SD-2, Hubel-1, HRB-1, GY-7, GY-14, and WF-3, respectively. doi:10.1371/journal.pone.0088328.g003

Table 3. Detection rates of rPDHB-based iELISA and the commercial kit.

| No. of sera | Detection results |
|-------------|------------------|
|             | Commercial kita  | rPDHB-based iELISA | Western blotb |
| 19          | 4+               | Positive          | NTc           |
| 71          | 3+               | Positive          | NT            |
| 38          | 2+               | Positive          | NT            |
| 15          | 1+               | Positive          | NT            |
| 176         | Negative         | Negative          | NT            |
| 39          | Negative         | Positive          | Positive      |

Detection rate (%)d 39.9 (143/358) 50.8 (182/358)

Kappa 0.783

*aPositive results were classified from 1+ to 4+ according to the kit protocol.
*bWestern blot analysis was performed to confirm that the sera were incompatible. It was performed using the whole-cell proteins of M. bovis strain PG45.
*cNT, not tested.
*dDetection rate = (number of positive samples/total number of samples) x 100.

doi:10.1371/journal.pone.0088328.t003

Discussion

M. bovis has caused severe losses to the worldwide cattle industry. Currently, only a few M. bovis vaccines, including bacterin and autogenous vaccines, have been approved in the United States. However, most bacterin-based vaccines cannot provide complete protection. In some cases, vaccination did not bring down the morbidity and mortality but even aggravated the symptoms instead [19–21]. For this reason, laboratory diagnosis is of great significance to the prevention and treatment of M. bovis infection. Because M. bovis infection is often latent and the bacterium is seldom shed from healthy cattle, serological detection of M. bovis antibody, which can last for several months and can be detected at high levels by ELISA, is considered a more reliable method of diagnosis of M. bovis infection [5]. However, commercial kits based on the whole-cell proteins currently used for serological diagnosis of M. bovis infection cannot ensure the detection of the variegated M. bovis isolates, and the development of ELISA using the specific conserved antigen with higher specificity and sensitivity is considered a promising alternative. Therefore, the exploitation of M. bovis proteins with excellent immunogenicity is necessary to the renewal and improvement of M. bovis diagnostic techniques. In the present study, immunoproteomics was used to screen the immunogenic proteins from a M. bovis strain isolated in China. Information regarding the immunogenic proteins identified in this way can provide a reference for the diagnosis of M. bovis infection.

Immunoproteomics involves combining 2-DE, immunoblotting, and mass spectrometry for analysis of functional proteins. In recent years, the immunoproteomics approach has seen increasingly widespread use in the diagnosis and vaccine research of important livestock pathogenic mycoplasmas, such as Mycoplasma capricolum subsp. capripneumoniae (Mccp), M. hyopneumoniae, and Mycoplasma hyorhinis [15,18,22]. However, it has seen less use in research into M. bovis. Thomas et al. performed 2-DE and MS to analyze the protein expression differences between the 7th and 116th generation of M. bovis strains [23]. Then an undiscovered adhesive protein as a new member of the Vsp family was identified. The study also showed that the phenotype of M. bovis may change after a long-term culture in vitro. For this reason, only the first three generations of M. bovis field-isolate strain PD were used for the preparation of protein samples in the present study. It was to prevent any change in M. bovis antigen proteins caused by long-term culture in vitro from affecting the results. Moreover, whole-cell proteins served as the protein sample for 2-DE instead of membrane proteins to
prevent the loss of important cytoplasmic antigen proteins [12]. Joerg et al. demonstrated the importance of antiserum selection in the immunogenic protein screening process [15]. They screened out 24 immunogenic proteins using serum obtained from the cattle that had been experimentally infected with *MmmSC* B237, but 13 additional proteins were detected when serum from the cattle with clinical acute onset was used. It indicated that the antibody induced in the naturally infected cattle is indispensable to the screening of immunogenic proteins of *M. bovis*. For this reason, strongly positive antisera from the cattle with natural onset were used in the present study for Western blot analysis to ensure that as many immunogenic proteins as possible would be recognized.

In the present 2-DE assay, about 570 and 338 prominent protein spots were separated in the gels with pH 3–10 and 4–7 IPG strips, respectively. According to the information provided by NCBI, there are 765 proteins encoded by *M. bovis* genome, which means that the present study acquired a proteome coverage of over 70%. It is similar to that observed in proteomic studies of other mycoplasma species [14,15,24]. Later, 19 immunogenic proteins were identified by Western blot and MALDI-TOF/TOF MS analysis. Most of these proteins were cytoplasmic proteins that were mainly involved in cell metabolism, cellular processes and signaling, and information storage and processing. Some of them were also related to adherence and invasion of host cells. Remarkably, some immunogenic proteins from other mycoplasma species have already been reported. These included PDHA, PDHB, GAPDH, L-lactate dehydrogenase (LDH), and translation elongation factors [15,22,25]. GAPDH is a highly conserved protein, and one of the features of GAPDH is its presence on the cell surface of several prokaryotic and eukaryotic cells, where it is able to bind mucin perhaps contributing to adherence to the epithelia [26]. In 2007, a study performed by Perez-Casal and Pryslik suggested that *M. bovis* GAPDH is an important immunogenic protein and might be a good candidate for diagnosis and vaccines [27]. However, they subsequently found that although cattle vaccinated with a subunit vaccine based on GAPDH produced high titers of IgG1 antibodies, there were few differences in the number of lung lesions and survival rate after challenge with a combination of three *M. bovis* isolates [12]. It indicates that screening and exploiting new immunogenic proteins are very necessary to the diagnosis and prevention of *M. bovis* infection. EF-Tu, EF-Ts, and EF-G are three factors usually involved in the protein translation process in prokaryotic cells. Elongation factor thermo stable proteins (EF-Ts) serve as guanine nucleotide exchange factors for elongation factor thermo unstable proteins (EF-Tu), catalyzing the release of guanosine diphosphate from EF-Tu. It allows EF-Tu to bind to a new guanosine triphosphate molecules, release EF-Ts, and go on to catalyze another aminoacyl tRNA addition. The EF-Tu proteins of many pathogens, including mycoplasmas, bacteria, and parasites have been reported to be immunoreactive [25,28,29]. EF-Tu has also been described as surface-localized, which allows it to mediate binding of *M. pneumoniae* to fibronectin [16]. In the present study, *M. bovis* EF-Ts was found to be immunoreactive. The issues of whether EF-Ts is antigenic conserved or involved in the adherence to host cells merit further study.

Pyruvate dehydrogenase (E1), dihydrolipoyl transacetylase (E2), and dihydrolipoyl dehydrogenase (E3) catalyze the conversion of pyruvic acid to acetyl CoA. With other cofactors, they form pyruvate dehydrogenase complex (PDHC). This conversion is a bond linking glycolysis and the tricarboxylic acid cycle. E1 is an α2β2 tetramer. It mainly catalyzes decarboxylation of pyruvate. Some studies have demonstrated that mycoplasma PDHB (beta subunit of E1) is a phosphoprotein with a cytoskeleton-like structure, and it can also be expressed on the surfaces of mycoplasma cells. Its primary roles are biosynthetic and metabolic and take place in the cytoplasm, but it is also involved in binding to the surface of the host cell. Previous studies have suggested that the conformation that PDHB assumes on the surface of the membrane may confer biological and virulence-related functions [16,17]. Zhao et al. identified nine proteins, including PDHB, in the membrane protein fraction of *Mycoplasma capricolum subsp. capripneumoniae* using a MS system that reacted with convalescent sera in the immunoblots [22]. Pinto et al. identified five highly immunoreactive antigens, including the PDHB of the *M. hypomunnea* pathogenic strain 7448, using immunoproteomics [18].

The present study is the first to find *M. bovis* PDHB to exhibit excellent immunogenicity and repeatability. Homology analysis indicated that the amino acid sequences of PDHB of different *M. bovis* isolates were nearly identical (≥99.7%). With one exception, *M. bovis* PDHB had less than or equal to 66.2% homology with any other mycoplasma species isolated from cattle, sheep, or goats. It exhibited 98.2% homology with *M. agalactiae* PDHB. We examined the antigenicity of *M. bovis* PDHB by Western blot assay, the presence of specific strips observed in all eight *M. bovis* field isolates probed with the rabbit anti-rPDHB polyclonal antibody demonstrated that this protein is structurally and antigenically conserved within the *M. bovis* cluster. For other species of pathogens from ruminants, cross-reactivity was detected solely with *M. agalactiae* which infects sheep and goats. *M. agalactiae* is considered to be the classical agent of contagious agalactia, which occurs worldwide and is one of the principal mycoplasmoses of sheep and goats. *M. bovis* and *M. agalactiae* are closely related both phenotypically and genotypically. *M. bovis* was once called *M. agalactiae* subsp. *bovis* [5]. They share a 16S rDNA similarity of 99.8% and an unusually high number of related antigens and common epitopes. The existence of cross reactivity is not unexpected between *M. bovis* and *M. agalactiae*. However, epidemiological investigations have shown *M. bovis* to be generally

### Table 4. Sensitivity of rPDHB-based iELISA and the commercial kit.

| Detection methods          | Dilutions of the sera |
|----------------------------|-----------------------|
|                            | 1:320                 |
| Commercial kit (no. of positive/total no.) | 140/140<sup>a</sup> |
| rPDHB-based iELISA (no. of positive/total no.) | 140/140<sup>a</sup> |
|                            | 1:640                 |
|                            | 1:1280                |
|                            | 1:2560                |
|                            | 1:5120                |
|                            | 1:10240               |
|                            | 1:20480               |

Different lowercase letter superscripts indicate significant differences (P<0.05).

doi:10.1371/journal.pone.0088328.t004
host-specific. Although *M. agalactiae* has been isolated from cattle on extremely rare occasions, the roles of *M. bovis* and *M. agalactiae* as pathogens outside cattle and small ruminants, respectively, have yet to be defined [30]. Most studies indicated that the probability of cross-reaction between *M. bovis* and *M. agalactiae* is very low in clinical situations. Therefore, this cross-reactivity is expected to have a negligible effect on the serologic diagnosis of *M. bovis* infection in most of the countries in which farms that raise both cattle and small ruminants are rare [10].

Based on these considerations, an iELISA with rPDHB as a diagnostic antigen was established to detect anti-*M. bovis* antibody. A commercial ELISA kit was used to assess the detection rate and sensitivity of the rPDHB-based iELISA. The comparative analysis between the two methods was carried out by testing 358 serum samples, the detection rate of the iELISA (50.8%) was higher than that of the commercial kit (39.9%), even though the two methods showed a good consistency (kappa = 0.783, where 1.0 is perfect consistency). Furthermore, rPDHB-based iELISA showed a significantly higher detection rate than the commercial kit at a serum dilution ratio of 1:2560 to 1:10,240, suggesting that rPDHB-based iELISA would be a better method for clinical detection with the higher sensitivity. In terms of the specificity of rPDHB-based iELISA, no cross-reaction was detected with the positive sera of other pathogens except *M. agalactiae*. As described above, the cross-reaction between *M. bovis* and *M. agalactiae* should not limit the establishment of this new ELISA detection method for *M. bovis*.

In conclusion, 19 immunogenic proteins of *M. bovis* were identified for the first time using 2-DE and MALDI-TOF/TOF MS approaches. An iELISA used to detect serum antibodies of *M. bovis* was established with rPDHB expressed in a prokaryotic MS approaches. An iELISA used to detect serum antibodies of *M. bovis* above, the cross-reaction between positive sera of other pathogens except rPDHB-based iELISA, no cross-reaction was detected with the detection with the higher sensitivity. In terms of the specificity of rPDHB-based iELISA would be a better method for clinical consistency). Furthermore, rPDHB-based iELISA showed a good consistency (kappa = 0.783, where 1.0 is perfect specificity). Furthermore, rPDHB-based iELISA showed a significantly higher detection rate than the commercial kit at a serum dilution ratio of 1:2560 to 1:10,240, suggesting that rPDHB-based iELISA would be a better method for clinical detection with the higher sensitivity. In terms of the specificity of rPDHB-based iELISA, no cross-reaction was detected with the positive sera of other pathogens except *M. agalactiae*. As described above, the cross-reaction between *M. bovis* and *M. agalactiae* should not limit the establishment of this new ELISA detection method for *M. bovis*.

In conclusion, 19 immunogenic proteins of *M. bovis* were identified for the first time using 2-DE and MALDI-TOF/TOF MS approaches. An iELISA used to detect serum antibodies of *M. bovis* was established with rPDHB expressed in a prokaryotic system. It can provide the supplementary diagnosis to the infectious *Mycoplasma bovis* pneumonia in cattle and advance the associated epidemiological investigation and quarantine.

Materials and Methods

Ethics statement

All animal research was approved by the Beijing Association for Science and Technology (approval ID SYXX (Beijing) 2007-0023) and was in compliance with Beijing Laboratory Animal Welfare and Ethics guidelines as issued by the Beijing Administration Committee of Laboratory Animals. All animal studies were also performed in accordance with the China Agricultural University Institutional Animal Care and Use Committee guidelines (ID: SKLAB-B-2010-003) and approved by animal welfare committee of China Agricultural University.

Mycoplasmas and culture conditions

*M. bovis* strain PD was used in this study. It was isolated in Shandong Province and stored in the laboratory. It was cultivated at 37°C in PPLO broth (BD, U.S.) containing 2.5% yeast extract (w/v), 20% horse serum (v/v), 0.5% phenol red (v/v) and 2000 IU/l penicillin. pH was maintained at 7.4–7.6.

Preparation of serum samples

The 358 serum samples and the corresponding nasal swabs were collected from cattle feedlots in Beijing, Shandong, Hebei, Tianjin, Hubei, Hunan, and Heilongjiang, all of which are in China. Some of these samples were taken from cattle that showed symptoms of *M. bovis* infection, such as fever, arthritis, mastitis, conjunctivitis, and pneumonia. PCR amplification and commercial ELISA (*Mycoplasma bovis* Antibody Test Kit, BioVet, Canada) were carried out separately on all samples [31,32]. The serum samples were kept at –70°C for further study of screening immunogenic protein and establishment of a method of detection.

**Extraction of the whole-cell proteins**

A modified version of a previously described method was used to extract *M. bovis* proteins [33]. Briefly, cells were harvested at a density of 10⁸ CFU/ml by centrifugation at 4°C and 12,000 g for 20 min and then resuspended in lysis buffer (7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 1% (w/v) DTT, 1% (v/v) cocktail, 0.5% (v/v) IPG buffer and 40 mM Tris-base, pH 9.6). Then cells were sonicated for 10 min on ice with a Sonifier 750 (Branson Ultrasonics Corp., U.S.). The proteins were collected by centrifugation at 4°C, 100,000 g for 1 h and lyzed in the same lysis buffer at room temperature (RT) for 1 h. The protein concentration was determined using a 2-D Quant Kit (GE Healthcare, U.S.).

**2-DE**

Isoelectric focusing (IEF): IEF was performed as described previously [34]. Briefly, each pH 3–10 IPG strip (17 cm, NL) or pH 4–7 IPG strip (7 cm, NL) was rehydrated at RT for 12 h with 350 µg or 100 µg *M. bovis* protein sample in 400 µl or 150 µl rehydration sample buffer (6 M urea, 2 M thiourea, 4% (w/v) CHAPS, 65 mM DTT, 0.5% (v/v) IPG, 0.04% (w/v) Bromophenol blue and 40 mM Tris-base, pH 9.6). IEF was performed in a PROTEAN® IEF System (Bio-Rad, U.S.). The parameters used for IEF were as follows: 50 V for 2 h, 500 V for 30 min, 1000 V for 30 min, 8000 V for 4 h. The final phase of 8000 V was terminated after 50,000 Vh.

SDS-PAGE: After IEF, the IPG strips were successively equilibrated for 15 min in equilibration buffer I containing 64.8 mM DTT and buffer II containing 135 mM iodoacetamide. Two equilibrated IPG strips were subjected to 12% polyacrylamide gel electrophoresis and sealed with 0.5% agarose solution. The second dimension was carried out at 50 V for 3 h followed by 100 V for 15 h. One strip gel was stained with Coomassie brilliant blue R-350, and the other was subjected to immunoblotting. The stained gel was scanned with an Image Scanner (Amersham Biosciences, U.S.) and analyzed using the PDQuest Basic 8.0 program (Bio-Rad). Three replicates were performed.

Immunoblotting

The separated protein spots from 2-DE gels were electroblotted onto PVDF membranes (Amersham Biosciences) using a trans-blot semi-dry transfer cell (Bio-Rad, U.S.). Blotted membranes were blocked with 10% (v/v) sheep serum (Macgene, China) in PBST (0.5% v/v Tween). Then the membranes were incubated with four anti-*M. bovis* positive sera tested with both a commercial kit and PCR (Table S1) diluted 1:800 at 4°C overnight, respectively. Three replicates were performed with each positive serum. HRP-conjugated sheep anti-bovine IgG (Sigma, USA; 1:8000 dilution) was used as the secondary antibody at RT for 30 min. Finally, the membranes were treated with Super Enhanced Chemiluminescent Substrate (ECL) Plus (Applygen, China) in accordance with the manufacturer’s instructions. Sera from healthy cattle served as negative controls.

**MALDI-TOF/TOF MS and bioinformatic analysis**

Immunoreactive protein spots were manually excised from Coomassie stained gels and in-gel digested with trypsin. Briefly, gel pieces were digested with 30% acetonitrile (ACN) in 100 mM NH₄HCO₃ and dried in vacuum centrifuge at RT. Then they were digested overnight in 12.5 ng/µl trypsin in 25 mM
Expression of rPDHB

Sequence analysis showed M. bovis PDHB to contain a UGA codon. This codon is translated as tryptophan according to mycoplasma genetic code but translated as a stop codon in the E. coli expression system. To avoid the production of truncated gene products, this UGA codon was mutated to UGG using two PCR products, this UGA codon was mutated to UGG using two PCR runs by standard overlap extension PCR (39). Two restriction enzyme cutting sites, Nco I and Xho I, were added to the flanks of the PDHB gene sequence. The mutagenic primers and flanking enzyme cutting sites, Nco I and Xho I, were added to the flanks of the PDHB gene sequence. Then PDHB gene fragment was cloned into a pET-28a(+) vector. Transetta (DE3) chemically competent cell (TransGen Biotech, China) was then transformed with the recombinant protein. Briefly, the competent cells carrying pET-28a(+) vector were grown in Luria-Bertani (LB) media at 37°C for 3 h and induced with 1 mM isopropyl-β-D-thiogalactoside (IPTG) for 4 h. Then the harvested cells were disrupted by sonication and recombinant proteins were purified by affinity chromatography. The corresponding protein sequence was downloaded from NCBI. Then the protein function classification was determined by comparison to COGs database with RPS-BLAST program, and the subcellular localization was predicted by PSORTb version 3.0 software.

Preparation of polyclonal antibody against rPDHB

Three New Zealand white rabbits aged 6–7 weeks were injected subcutaneously with purified rPDHB (0.5 mg/kg) three times at 2-week intervals. rPDHB was blended with the same volume of complete Freund’s adjuvant (CFA, Sigma) in the first immunization and with incomplete Freund’s adjuvant (IFA) in the following immunization. A rabbit injected with adjuvants alone served as a negative control. Sera were collected two weeks after the last immunization and the antibody titers were tested using ELISA. The positive sera were either tested for specificity by Western blot analysis or stored at –70°C.

Table 5. Primers used for expression of rPDHB in the present study.

| Name             | Sequence* | Description                                           |
|------------------|-----------|-------------------------------------------------------|
| MbPDHB-F         | 5′-TGAGAAAATTTTCATTTAATAAC | Forward primer specific to the PDHB gene of M. bovis |
| MbPDHB-R         | 5′-TTAGCCCTAACATTCTCCGATAAC | Reverse primer specific to the PDHB gene of M. bovis |
| MbPDHB-A         | 5′-CAGCCATTGCGAGAAATAACCTTCCAATAAAC | Forward primer containing a Nco I site for cloning into pET-28a (+) |
| MbPDHB-B         | 5′-CAGTTGCTATGCTGACTCTTGTGATC | Primer for site-directed mutagenesis |
| MbPDHB-C         | 5′-GGTGCACAAAGAGATGGTGGACCTCCAAATTTC | Primer for site-directed mutagenesis |
| MbPDHB-D         | 5′-CGGCTCGGAGGCTAACATTCTCCGATAAC | Reverse primer containing a Xho I site for cloning into pET-28a (+) |

*The restriction endonuclease sites are underlined. doi:10.1371/journal.pone.0088328.t005

Establishment of rPDHB-based ELISA

Indirect ELISA was performed as described previously [10]. Briefly, 96-well ELISA plates were coated with 25, 50, 100, 200, or 400 ng/well rPDHB and allowed to incubate at 4°C overnight. Sheep serum, swine serum, horse serum, protein-free blocking buffer, and gelatin served as blocking buffers. Sera (primary antibodies) were diluted to 1:40, 1:80, and 1:160–1:2560 (v/v). HRP-conjugated sheep anti-bovine IgG secondary antibody was diluted to 1:1000, 1:2000, 1:4000, and 1:8000 (v/v). Finally the substrate TMB and 2 M H2SO4 was added for coloration and termination of the reaction, respectively. The plates were read at an optical density of 450 nm (OD450) with a reference filter of 630 nm in an ELISA plate reader (Pharmacia, U.S.).

Fifty OD450 values of negative sera presenting normal distribution were used to calculate the mean optical density (OD) and standard deviation (SD). The cutoff value between positive and negative sera was calculated as the mean OD of the fifty negative sera plus 3 SDs of the mean. This calculation provides 99% confidence that all negative values fell within the defined range [35,36].

Specificity

Two methods were used to confirm the specificity of M. bovis PDHB: i) Whole-cell proteins from M. agalactiae (CVCC 344), M. bovirhinis (ATCC 27748), M. ovispneumoniae (ATCC 29419), BVDV (CVCC AV-69), BPIV3 (ATCC VR-281), IBRV (CVCC AV-346), and eight M. bovis strains were used to assess cross-reactivity with anti-rPDHB polyclonal antibodies in Western blot assays. The eight M. bovis strains were M. bovis PG45 (ATCC 25523), M. bovis Hubei-1 (donated by China Animal Health and Epidemiology Center), M. bovis SD-2 (donated by China Animal Health and Epidemiology Center) and five strains preserved in the lab, specifically M. bovis PD, M. bovis HRB-1, M. bovis GY-7, M. bovis GY-14, and M. bovis WF-3. ii) rPDHB-based ELISA was used to detect three rabbit polyclonal antibodies against M. bovirhinis, M. bovis, and M. ovipneumoniae.
agalactiae, and M. ovipneumoniae (prepared using the method described above), and four positive sera of MmnSC, BVDV, BPIV3, and IBRV that had been purchased from Real Biotechnology (China). All protein samples were boiled before being loaded onto the SDS-PAGE gel. The parameters used to transfer the gels to the PVDF membrane included 60 V for 2 h. All the pathogens described above were identified using specific PCR. The primer sequences and the references are given in Table S2.

rPDHB-based iELISA and commercial kit

The 358 serum samples were tested using rPDHB-based iELISA under optimized conditions, and the degree of agreement and sensitivity between the iELISA and the commercial kit were determined.

Sensitivity: 140 positive serum samples and 20 negative controls were randomly selected. Twofold serial dilutions of the sera from 1:30 to 1:20,480 were employed in the test. The commercial kit and rPDHB-based iELISA were used separately for detection. Samples with OD450 values greater than or equal to twice that of the negative serum were considered positive (A 630 nm filter served as a reference filter).

Statistical analysis

The degree of agreement between the commercial kit and rPDHB-based iELISA was measured using kappa statistics [37]. The sensitivity of the detection of differences between the rPDHB-based iELISA and commercial kit were analyzed using the Chi-square or Fisher’s Exact test with SPSS v19.0 software. P values below 0.05 were considered statistically significant.

Supporting Information

Figure S1 Antigenicity analysis of M. bovis PDHB. M. bovis rPDHB (lane 1) and the whole-cell proteins of M. bovis (lane 2), M. agalactiae (lane 3), M. bovirhinis (lane 4), M. ovipneumoniae (lane 5), BVDV (lane 6), BPIV3 (lane 7) and IBRV (lane 8) were separated by SDS-PAGE, blotted onto a PVDF membrane and subjected to the following Western blot analysis with rabbit anti-M. bovis rPDHB polyclonal antibody.

(TIF)

Figure S2 PCR identification of the pathogens used in the present study. Photograph of a 1% agarose gel loaded with the PCR or RT-PCR (for RNA viruses: BVDV and BPIV3) products. M: molecular weight marker. Lane 1-7: M. bovis, M. agalactiae, M. bovirhinis, M. ovipneumoniae, BVDV, BPIV3, and IBRV, respectively. The specific primers are listed in Table S2.

(TIF)

Table S1 Positive bovine sera used in the immunoblot assays.

(DOC)

Table S2 Primer sequences used for PCR identification.

(DOC)

Acknowledgments

We would like to thank Huiling Chen and Wenqiang Gan for providing the bovine sera. We would also like to thank Xiaolin Zhu and Ming Zhou for improving the English of the manuscript.

Author Contributions

Conceived and designed the experiments: ZHS PF KW WXW. Performed the experiments: ZHS PF HYZ WXW. Analyzed the data: ZHS PF KW HYZ WXW. Contributed reagents/materials/analysis tools: WXW. Wrote the paper: ZHS PF KW WXW.

References

1. Hale HH, Helmholdt CF, Plaister W, Stula EF (1962) Bovine mastitis caused by a Mycoplasma species. Cornell Vet 52: 582-591.
2. Pfutzner H, Sachse K (1996) Mycoplasma bovis as an agent of mastitis, pneumonia, arthritis and genital disorders in cattle. Rev Sci Tech 15: 1477-1494.
3. Xin JQ, Li Y, Guo D, Song SH, Hu SP, et al. (2000) First isolation of Mycoplasma bovis from calf lung with pneumonia in China. Chinese Journal of Preventive Medicine 30: 661-664.
4. Tschope R, Bonnemain P, Nicolet J, Burnens A (2001) Epidemiological study of risk factors for Mycoplasma bovis infections in fattening calves. Schweiz Arch Tierheilkd 143: 461-467.
5. Nicholas RA, Ayling RD (2003) Mycoplasma bovis: disease, diagnosis, and control. Res Vet Sci 74: 105-112.
6. Caswell JL, Arghambah M (2007) Mycoplasma bovis pneumonia in cattle. Anim Health Res Rev 8: 161-166.
7. Lymnyanskiy I, Rosengarten R, Yogeov D (1996) Phenotypic switching of variable surface lipoproteins in Mycoplasma bovis involves high-frequency chromosomal rearrangements. J Bacteriol 178: 5399–5407.
8. Nussbaum S, Lymnyanskiy I, Sachse K, Levisohn S, Yogeov D (2002) Extended repertoire of genes encoding variable surface lipoproteins in Mycoplasma bovis strains. Infect Immun 70: 2220-2225.
9. Sachse K, Pfutzner H, Heller M, Hanel I (1993) Inhibition of Mycoplasma bovis cytadherence by a monoclonal antibody and various carbohydrate substances. Vet Immunol Immunopathol 36: 307–316.
10. Rothen P, Alberti A, Pittau M, Chessa B, Micletta M, et al. (2005) Genetic and antigenic characterization of the surface lipoprotein P48 of Mycoplasma bovis. Vet Microbiol 109: 201-209.
11. Scherm B, Gerlach GF, Runge M (2002) Analysis of heat shock protein 60 encoding genes of mycoplasmas and investigations concerning their role in immunity and infection. Vet Microbiol 89: 141-150.
12. Prysliak T, van der Merwe F, Perez-Casal J (2013) Vaccination with recombinant Mycoplasma bovis GAPDH results in a strong humoral immune response but does not protect feedlot cattle from an experimental challenge with M. bovis. Microb Pathog 12: 1-8.
13. Jaffe JD, Berg HC, Church GM (2004) Proteogenomic mapping as a complementary method to perform genome annotation. Proteomics 4: 59-77.
14. Uhrbele B, Frank R, Herrmann R (2002) The proteome of the bacterium Mycoplasma pneumoniae: comparing predicted open reading frames to identified gene products. Proteomics 2: 754-764.
15. Jonas J, Meens J, Baertner FF, Linz B, Naessens J, et al. (2009) Analysis of the immunoproteome of Mycoplasma mycoides subsp. mycoides small colony type reveals immunogenic homologues to other known virulence traits in related Mycoplasma species. Vet Immunol Immunopathol 131: 231-245.
16. Fallo SF, Kanan TR, Blaylock MW, Baseman JB (2002) Elongation factor Tu and El β-subunit of pyruvate dehydrogenase complex act as fibronectin binding proteins in Mycoplasma pneumoniae. Mol Microbiol 46: 1041–1051.
17. Su HC, Hutcison CA 3rd, Giddings MC (2007) Mapping phosphoproteins in Mycoplasma genitalium and Mycoplasma pneumoniae. BMC Microbiol 7: 47-63.
18. Pinto PM, Chemale G, de Castro LA, Costa AP, Kich JD, et al. (2007) Proteomic survey of the pathogenic Mycoplasma hyopneumoniae strain 7448 and identification of novel post-translationally modified and antigenic proteins. Vet Microbiol 121: 83-93.
19. Soehnlen MK, Aydin A, Lengerich EJ, Houser BA, Fenton GD, et al. (2011) Blinded, controlled field trial of two commercially available Mycoplasma bovis bacterins vaccines in veal calves. Vaccine 29: 5347–5354.
20. Maunsell FF, Woomah AR, Francoz D, Rosenbusch RF, Step DL, et al. (2011) Mycoplasma bovis infections in cattle. J Vet Intern Med 25: 772-783.
21. Maunsell FF, Donovan GA (2009) Mycoplasma bovis infections in young calves. Vet Clin North Am Food Anim Pract 25: 139-147.
22. Zhao P, He Y, Chu YF, Gao PC, Zhang X, et al. (2012) Identification of novel immunogenic proteins in Mycoplasma capricolum subsp. Capripneumoniae strain M1601. J Vet Med Sci 74: 1199-1211.
23. Thomas A, Lepiniec P, Dzierz I, Ball H, Gevaert K, et al. Identification by two-dimensional electrophoresis of a new adhesin expressed by a low-passage strand of Mycoplasma bovis. Res Microbiol 156: 713-718.
24. Wasinger VC, Pollack JD, Humphery-Smith I (2000) The proteome of Mycoplasma genitalium. Chaps soluble component. Eur J Biochem 267: 1571–1592.
25. Alonso JM, Prieto M, Parra F (2002) Genetic and antigenic characterization of elongation factor Tu from Mycoplasma mycoides subsp. mycoides SC. Vet Microbiol 89: 277-289.
26. Alvarez RA, Blaylock MW, Baseman JB (2003) Surface localized glyceraldehyde-3-phosphate dehydrogenase of Mycoplasma genitalium binds mucin. Mol Microbiol 48: 1417–1425.

27. Perez-Casal J, Prysiak T (2007) Detection of antibodies against the Mycoplasma bovis glyceraldehyde-3-phosphate dehydrogenase protein in beef cattle. Microb Pathog 43: 189–197.

28. Sun XM, Ji YS, Elashrama SA, Lu ZM, Liu XY, et al. (2012) Identification of antigenic proteins of Toxoplasma gondii RH strain recognized by human immunoglobulin G using immunoproteomics. J proteomics 77: 423–432.

29. Yang YL, Wang L, Yin JG, Wang XL, Cheng SP, et al. (2011) Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine. Mol Immunol 49: 175–184.

30. Bashiruddin JB, Frey J, Konagston MH, Johansson KE, Hotzel H, et al. (2005) Evaluation of PCR systems for the identification and differentiation of Mycoplasma agalactiae and Mycoplasma bovis: a collaborative trial. Vet J 169: 268–273.

31. Hou X, Fu P, Zhang HY, Zhang YW, Wu WX (2012) Development of loop-mediated isothermal amplification for rapid detection of Mycoplasma bovis. Journal of Agricultural Biotechnology 20: 210–224.

32. Tenk M, Balint A, Stipkova L, Biro J, Deraco L (2006) Detection of Mycoplasma bovis with an improved per assay. Acta Vet Hung 54: 427–435.

33. Regula J, Ueberle B, Boguth G, Gorg A, Schnolzer M, et al. (2000) Towards a two-dimensional proteome map of Mycoplasma pneumoniae. Electrophoresis 21: 3765–3780.

34. Gorg A, Weiss W, Dunn MJ (2004) Current two-dimensional electrophoresis technology for proteomics. Proteomics 4: 3665–3685.

35. Webster KA, Giles M, Dawson C (1997) A competitive ELISA for the serodiagnosis of hypodermitis. Vet Parasitol 68: 155–164.

36. Tiwari S, Kumar A, Thavaselvam D, Mangalgi S, Rathod V, et al. (2013) Development and comparative evaluation of a plate enzyme-linked immunosorbent assay based on recombinant outer membrane antigens Omp28 and Omp31 for diagnosis of human brucellosis. Clin Vaccine Immunol 20: 1217–1222.

37. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33: 159–174.